Charcot-Marie-Tooth (CMT) disease is caused by mutations in several genes expressed in myelinating Schwann cells and the axons they ensheathe. Typical patients present with distally accentuated motor weakness, muscle wasting, and sensory loss leading to significant and progressive clinical morbidity and impaired quality of life. The wealth of recent information regarding genotype-phenotype correlations, recognition of disease heterogeneity, and newly characterized animal models provide exciting insights into the molecular disease-related pathogenetic and pathophysiologic mechanisms. These advances at the same time also represent a challenge for the diagnosis and management of these patients, with no presently available specific curative or disease modifying treatments. A better understanding of the pathogenesis of peripheral neuropathies is an invaluable tool in developing future supportive and curative therapies for patients with CMT disease that will improve their quality of life. In this review, we provide practical insights on current diagnostic and therapeutic modalities and suggest future diagnostic and therapeutic directions.
most patients with CMT could be divided into two groups, one with slow nerve conduction velocities and pathological evidence of a hypertrophic demyelinating neuropathy (CMT type 1 [CMT1]), and another with relatively preserved nerve conduction velocities with pathological evidence of axonal loss (CMT type 2 [CMT2]). [10] [11] [12] [13] Patients with CMT1 were found to have median motor nerve conduction velocities below 38 m/s, whereas median motor nerve conduction velocities were greater than 38 m/s in patients with CMT2. Approximately 75% of the patients belonging to the first group, similar to the ones described by Charcot, Marie, and Tooth, were found to have an autosomal-dominant pattern of inheritance, weakness, and sensory loss predominantly in the distal legs, and muscle wasting in the distribution of weakened muscles. Most patients presented within the first two decades of life. However, sporadic occurrence observed in 25% of patients suggested a different inheritance pattern, such as autosomalrecessive or potentially new dominant mutations.
RECLASSIFICATION OF CHARCOT-MARIE-TOOTH DISEASE: THE MOLECULAR ERA
The electrophysiological dichotomy of demyelinating and axonal CMT neuropathies (as reflected in the original classification by Dyck and Lambert [ Table 1 ]) was supported by early experimental data from transgenic animal models, 14, 15 which linked the demyelinating and axonal forms of CMT to primary defects in Schwann cell and axonal function. This concept had to be revised, however, when it was recognized that despite obvious similarities among patients with CMT1, the group is genetically heterogeneous. The most common form of CMT1, CMT1A, was associated with a 1.4 Mb duplication at chromosome 17p11.2. 16, 17 Reports of other genetic defects associated with hereditary neuropathies soon followed. CMT1B, linked to chromosome 1, is caused by mutations in the gene of myelin protein zero (MPZ) glycoprotein; X-linked neuropathy, CMTX1, is due to mutations in the gap junction (GJB1) on the X chromosome encoding the gap junction protein, connexin 32. Deletion of the identical 1.4-Mb region responsible for CMT1A is associated with hereditary neuropathy with susceptibility to pressure palsies (HNPPs). Dejerine-Sottas disease (DSD), a severe infantile neuropathy, is associated with mutations or deletions in peripheral myelin protein 22 (PMP22), MPZ, early growth response gene 2 (EGR2), and several other dominantly and recessively inherited genes. To date, at least 40 different forms of CMT have been described (http://www.molgen.ua.ac.be/ CMTMutations). This diversity also reflects a challenge in diagnosis and therapy, and has consequently led to the need to modify the traditional classification system. Genotype-phenotype studies have been an invaluable 19, 20 We know now that most of these neuropathies are related to mutations in the GJB1 gene causing X-linked CMT. 21, 22 More recently, both dominant and recessive forms have been identified. These neuropathies do not fit easily into the original Dyck and Lambert classification scheme because of their X-linked inheritance and intermediately slow NCV. Classification schemes modified to accommodate the genetic causes of the neuropathy and inheritance pattern have been published.
2 CMT4 is used to classify the recessive forms of CMT, regardless of whether they are demyelinating or axonal. Another reason the classification schemes remain a challenge is that pathogenic mutations in the same genes are associated with different inheritance patterns, such as is seen in mutations in the PMP22 gene. A change from threonine to methionine at position 118 (Thr118Met) may appear to cause recessively inherited neuropathies, when in fact it is a dominantly inherited neuropathy where the mutation leads to partial gain of function of the affected gene. 23 Clinical variability related to mutations involving identical genes and phenotypical similarities noted in mutations associated with different genes invariably lead to challenges not only in classification, but also, consequently, in diagnosis and patient management. Table 1 presents some of the useful parameters that have been applied to classify CMT neuropathy.
EPIDEMIOLOGY
Early data on epidemiology of CMT were obtained before the era of molecular testing. Estimated prevalence of CMT neuropathies has been reported as 23 to 46 per 100,000 people in Northern Europe, 1 with comparable numbers reported by Dyck and colleagues in southeastern Minnesota. 13, 24 Harding and Thomas's cohort of 227 patients with CMT was comprised of 76% (173) CMT1 and 24% CMT2. 13 This correlates well with data reported by Dyck and Lambert in 1968. 10, 11 Increasing availability of commercial genetic testing allowed for new data about mutational frequencies worldwide. Databases from both North America and Europe previously have put the frequency of the most common form of CMT1, CMT1A, at $60 to 70%; CMTX accounts for $10 to 20%, and CMT1B for up to 5%. 22, 25, 26 HNPP is caused in $80% of cases by chromosome 17p11.2 deletion, 22 with most remaining cases likely to be related to point mutations in the PMP22 gene. 27, 28 More recent reports showed comparable mutation frequency in Chinese patients.
3 CMT2 accounts for $22% of dominantly inherited neuropathies in the series of Inonasescu et al. 29 Distribution of CMT mutations in the database at the CMT Clinic at Wayne State University is shown in Table 2 . These data are similar to mutational frequencies reported by other groups cited previously.
CLINICAL FEATURES OF INHERITED NEUROPATHY
Clinical classification of patients with CMT is based on establishing identifying features of an inherited peripheral neuropathy based on typical presentation, family history, and supporting electrophysiological and genetic testing. Making a clinical diagnosis in typical cases is no challenge for the experienced neurologist. Phenotypic variability of CMT neuropathies and scarce availability of natural history data are increasingly recognized, however. Taken together with newly presenting mutations, variable penetrance and progression rates between and within the same generations may lead to diagnostic challenges and ultimately the need for referral of these patients to special tertiary neurological centers for diagnosis and management. Clinical features of the different CMT phenotypes are presented in Table 3 .
PATHOGENESIS: GENOTYPE-PHENOTYPE CORRELATIONS
Many recent studies have investigated the molecular pathways underlying various forms of CMT. Understanding how different genetic defects lead to the development of disease phenotypes is a challenging, [30] [31] [32] but potentially very rewarding task because effective novel therapies may someday be developed based on these new discoveries.
Normal myelination implies the well-coordinated interaction of Schwann cells and axons. [33] [34] [35] Traditional classifications of CMT have emphasized the primarily demyelinating or axonal features of CMT based on the changes noted in nerve conduction velocities. In a very simplistic approach, this means that markedly reduced forearm motor nerve conduction velocities (below 38 m/s) are indicative of demyelination or a dysmyelination process, whereas normal motor nerve conduction velocities with markedly reduced nerve action potential amplitudes signal axonal pathology. However, recent data highlight the dynamic interaction between Schwann cell and axon during development; MPZ mutations may lead to a typical ''axonal'' CMT, 18 and primary disturbance of axonal signaling pathways may lead to hypomyelinated/dysmyelinated nerve fibers with slow nerve conductions, such as has been shown in the transgenic NRG1 mice. 36, 37 Axonal CMT and axon-glia interactions in various CMTs have been reviewed in detail elsewhere. 31 Table 4 lists the different mechanisms that are currently implicated in the pathogenesis of demyelinating and axonal CMT. Recognizing molecular mechanisms, how mutated proteins contribute to the clinical phenotypes, and in particular distinguishing the exact contribution of individual Schwann cell and neuronal genes to clinical disability may provide a means to further treatments.
DOES THE ELECTROPHYSIOLOGY REFLECT THE PATHOPHYSIOLOGY?
Introduction of nerve conduction studies (NCS) into neurological diagnosis has revolutionized the diagnosis of neuropathies. The obtained nerve conduction parameters provide valuable clues as to whether neuropathies are primarily demyelinating or axonal processes. Nerve conduction studies remain the primary test used to classify CMT because they are easily performed and minimally invasive. The principle that inherited and acquired demyelinating neuropathies could be distinguished in most cases by their nerve conduction velocities was introduced by Lewis and Sumner 31 with their recognition that inherited demyelinating neuropathies have uniformly slow nerve conduction velocities, whereas acquired demyelinating neuropathies, such as chronic inflammatory demyelinating polyradiculoneuropathy, have asymmetric or nonuniform slowing. Recent studies have pointed to some exemptions to this principle; even though most patients with CMT1, particularly those with CMT1A, have uniformly slow motor nerve conduction velocities of $20 m/s, values as high as 42 m/s have been reported (Fig. 1) , and are sometimes used as a cut-off value. Also, HNPP has been recognized for an asymmetric electrophysiological pattern. Asymmetric nerve conduction velocities may also be found in patients with missense mutations in PMP22, MPZ, EGR2 and GJB1. The usefulness of electrophysiology to guide the clinician in obtaining an accurate diagnosis is increasingly being reevaluated. Fig. 2 presents a possible guide for the clinician in making a diagnosis. Early on it was recognized that there is a group of CMT that is frequently referred to as ''intermediate'' CMT. 19, 39, 40 This term is being used without consensus in research publications and Medline to identify the group of patients with conduction velocities ''between'' CMT1 and CMT2 despite the obvious overlaps with CMT1 and CMT2. At this point, however, no clear criteria or definitions are available to clarify this entity or delineate the pathophysiology. CMTX patients constitute the majority of patients with intermediately slowed NCV. 21 Patients with CMTX and CMT1B may present with NCVs in the intermediate range but also with electrodiagnostic features misleadingly suggestive of a ''primarily axonal'' neuropathy (e.g., markedly reduced sensory nerve action potential [SNAP] and compound muscle action potential [CMAP] amplitudes [ Fig. 1]) . In such cases, however, distal motor latencies and Fwave latencies are usually prolonged, consistent with the underlying mutations in the Cx32 protein, a protein that is expressed in the myelinating Schwann cell. Similar issues occur in some patients with mutations in the MPZ gene (Thr118Met).
Because all of these disorders may appear de novo, one has to be careful in applying NCV parameters alone to separate acquired from inherited demyelinating neuropathies or to use them as a guide to distinguish between inherited neuropathies. 38 Electrodiagnostic assessment of inherited neuropathies is important, however, because CMAPs are considered a measure of axonal integrity, and it has been shown in clinical studies 41 that axonal loss correlates better with the patient's actual disability.
APPROACH TO DIAGNOSIS AND MANAGEMENT
Marked variations in phenotypic presentations represent a challenge in the diagnosis of CMT. It is well documented in patients with CMT that they may present with variable age of onset and different speed of symptom progression. 2 The diagnosis and management of the patient with CMT is best undertaken by a multidisciplinary approach that involves a neurologist, and, when appropriate, a genetic counselor, orthopedic surgeon, physiatrist, pulmonary specialist, physical therapist, occupational therapist, and/or social worker to provide the maximum care for patients with chronic disability.
It seems obvious that severe, early onset nerve dysfunction, such as seen in DSD and some of the early onset CMT1B patients, 18 puts a different type of burden on families and provides more challenges for healthcare providers than a slower, progressive, adult-onset form of the disorder that nonetheless may also lead to significant reductions in quality of life over time. 42 No clear estimates are currently available that assess the financial burden of this chronic disease on families and the healthcare system. Early diagnosis and, if possible, interventions impact the patient's day-to-day life in a positive way at multiple levels. [43] [44] [45] One of the most important issues is genetic testing and counseling. 46 Despite the increasing availability of commercial and research testing, CMT remains principally a clinical diagnosis established by signs and symptoms of examination, family history, and electrodiagnostic testing (Fig. 2) . 46, 47 Genetic testing supports the clinical and electrophysiological diagnosis, and at the same time genetic counseling is important for the patients and their families to help with disease prognosis. Decisions regarding genetic testing should be made in consensus with the individual family members. Distinction should be made regarding testing in affected or atrisk individuals. Appropriate indications for genetic testing may soon change as more genes causing neuropathy are identified and more is learned about the phenotypic range produced by mutations in these genes. For example, cases of CMT1B are now being reported with normal NCV; these would have been missed if genetic testing had not been performed.
Predictive testing of individuals at risk for CMT should be approached with more circumspection. A patient, along with a support person, should be seen by both a neurologist and genetic counselor and be counseled about the possible implications of testing with respect to their family relationships, insurance, and employability. Every effort should be made to obtain documentation of the disease in a relative. Testing is not recommended for asymptomatic children who are at risk for CMT, in agreement with the Statement of the Practice Committee Genetics Testing Task Force of the American Academy of Neurology (1996) . When a child is clearly showing symptoms of CMT, testing may be appropriate.
Other than establishing an individual's risk for the disease, genetic testing may also help delineate more accurate genotype-phenotype interactions. 46 Online resources are available and provide comprehensive information for both healthcare providers and patients (see Addendum).
MANAGEMENT
Management of hereditary neuropathies is aimed at complex supportive and, when available, curative treatment modalities. Table 5 provides a summary of current supportive treatment options, addressing leading symptoms. Treating physicians need to also be aware of potential dangers associated with iatrogenic complications associated with therapeutic interventions to be able to assess risk-benefit ratios and provide appropriate counseling for their patients. There is currently no cure for CMT. Basic research into therapeutic strategies is being done using transgenic animal models to develop new human applications. Gene therapy approaches for gene replacement are only possible in monogenic disorders if the mutation leads to clear loss of function. The gene dosage-dependent changes in CMT1A 48 or partial loss of function disease mechanism found in certain CMT1B (Thr118Met) patients represent a challenge to overcome despite advances in the field. 49, 50 It has been shown that clinical disability is related to axonal degeneration. 41 Therefore, the attempt to provide trophic support by neurotrophic factors is a promising approach. It is likely that despite promising results in animal models 51 more research needs to be done before this can be extrapolated to human applications. Further studies need to be performed regarding potential immunomodulatory therapies in CMT despite recent indications of improved myelination in immunodeficient transgenic mice.
52
THERAPY: NEW CLINICAL APPROACHES Ascorbic acid treatment of the animal model of CMT1A has improved myelination and reduced PMP22 levels in affected rats. A multicenter international clinical trial is already on the way that uses high-dose ascorbic acid for treatment in patients with CMT1A. 53 Another exciting new approach is based on data obtained in the animal model of CMT1A, which showed that a selective progesterone antagonist, onapristone, reduced PMP22 overexpression in tissue culture and improved the CMT phenotype in CMT1A rats. 54 
CONCLUSIONS
Inherited neuropathies are among the most prevalent genetic neurological diseases. They affect the quality of life of the patients by leading to marked disability due to progressive weakness and social and psychological burden. Treatment of this chronic disorder challenges families and healthcare workers. Developing treatments for patients will directly affect thousands of individuals. In addition, the genes and their proteins that cause inherited neuropathies serve as a source of molecules that are important for peripheral nerve function. Identifying the molecular pathways involved in these disorders will also lead to a better understanding of pathways involved in neurodegenerative disease in general.
ADDENDUM: RESOURCES FOR PATIENTS AND FAMILIES
Multiple resources exist for people with CMT to learn more about their disease, genetic conditions in general, where to find others in a similar situation, and keep abreast of new therapies and/or clinical trials. This addendum provides the path to some of these resources.
